Feline Renal Amyloidosis

Overview

A condition where an abnormal protein (amyloid) deposits within kidney tissue, progressively disrupting normal filtering function — distinct from the hepatic (liver) amyloidosis covered in its own entry, though both reflect the same underlying abnormal protein deposition process affecting a different organ, and notably, in some predisposed cat lines, both organs can be affected together.

Symptoms

• Protein in urine (often early finding) (mild, common)
• Increased thirst/urination (moderate, common)
• Weight loss (moderate, common)

Causes

Deposition of amyloid protein within kidney tissue, particularly affecting the glomeruli (the kidney's filtering units); a genetic predisposition is strongly suspected in certain breed lines, similar to the pattern discussed for hepatic amyloidosis. Deposition of an abnormal protein (amyloid) within kidney tissue progressively impairs normal kidney function — in cats, this shows a notable breed association with Abyssinians and related breeds, suggesting a genetic predisposition in these breeds specifically, distinct from the reactive/inflammatory-associated amyloidosis pattern seen in some other contexts.

Risk Factors

Breed is the primary known risk factor — Abyssinian cats are the breed most classically and strongly associated with renal amyloidosis specifically, with Siamese and related Oriental breeds also reported at elevated risk.

Transmission

Not infectious — reflects an individual cat's own abnormal protein deposition process, with a suspected genetic component in predisposed breeds.

Incubation Period

Not applicable in the infectious sense; a gradually progressive process.

Disease Stages & Progression

Amyloid progressively deposits within kidney tissue, disrupting normal filtering function over time, eventually leading to chronic kidney disease and, in more severe cases, kidney failure — this progression can occur at a younger age than typical age-related chronic kidney disease given the underlying genetic predisposition driving it.

Early Warning Signs

Protein loss in urine (proteinuria) may be an early, sometimes incidentally-discovered finding before more obvious kidney dysfunction symptoms develop.

Advanced Symptoms

Progressive kidney dysfunction symptoms — increased thirst and urination, weight loss, decreased appetite — similar to chronic kidney disease generally, but potentially occurring at a younger age in affected breeds.

Diagnostic Methods

Breed history combined with proteinuria and progressive kidney dysfunction raises suspicion; kidney biopsy showing characteristic amyloid deposits provides definitive diagnosis, though pursued carefully given some bleeding risk considerations similar to those discussed for hepatic amyloidosis. Kidney biopsy with special staining techniques confirms amyloid deposition; genetic and breed history can raise suspicion in predisposed breeds even before definitive biopsy confirmation.

Veterinary Examination Process

Assessment of hydration, body condition, and overall status; findings often reflect general chronic kidney disease presentation rather than anything specifically distinctive to amyloidosis on physical exam alone.

Recommended Lab Tests

Urine protein-to-creatinine ratio, kidney function panel, and biopsy for definitive diagnosis.

Diagnostic Imaging

Ultrasound may show kidney changes, though findings aren't always dramatically distinctive on imaging alone.

Blood Test Indicators

Elevated kidney values (BUN, creatinine) once function becomes significantly affected; urine protein-to-creatinine ratio testing detects the often-earlier finding of protein loss.

Biopsy / Histopathology

Provides definitive diagnosis, showing characteristic amyloid deposits within kidney tissue, particularly the glomeruli.

Differential Diagnoses

Standard chronic kidney disease, glomerulonephritis, and other causes of proteinuria — biopsy and breed history help distinguish amyloidosis specifically.

Home Monitoring Guidance

For an Abyssinian or related-breed cat, periodic veterinary monitoring including urine protein screening is more relevant than home monitoring alone, given this condition's tendency to develop without obvious early symptoms.

Veterinary Treatment Options

There's no treatment that reverses amyloid deposition; management follows the same general principles as chronic kidney disease once function declines — supportive kidney-focused diet and care, along with medication to reduce urinary protein loss where significant proteinuria is present.

Surgery Requirements

Not applicable to the underlying condition.

Recovery Timeline

Not applicable — a progressive condition managed rather than cured.

Possible Complications

Progressive chronic kidney disease and, in more severe cases, kidney failure.

Long-Term Management

Ongoing monitoring of kidney function and urine protein levels, alongside standard chronic kidney disease management once function declines.

Prevention

Genetic testing and informed breeding decisions in predisposed lines, similar to the approach discussed for hepatic amyloidosis, though not as rigorously established as testing protocols exist for some other specific genetic kidney conditions.

Vaccination Availability

Not applicable.

Prognosis

Variable, generally guarded once significant kidney dysfunction has developed, reflecting the progressive and currently irreversible nature of amyloid deposition. Amyloid deposition itself isn't reversible, and progression to significant kidney disease is common in affected cats, though the rate of progression varies — management follows a similar supportive approach to other causes of progressive kidney disease once function begins to decline.

References

American College of Veterinary Internal Medicine (ACVIM); breed-specific genetic health resources for Abyssinian cats.

Medications Used

• Medication to reduce urinary protein loss (similar to management of glomerulonephritis)
• Standard chronic kidney disease supportive medications once function declines

Estimated Treatment Cost by Country

Frequently Asked Questions